(HealthDay News) – While the majority of HIV patients with dyslipidemia or hypertension are treated, a significant percentage still do not have adequate control, according to a study published online April 11 in the Journal of Acquired Immune Deficiency Syndromes.

Merle Myerson, MD, EdD, from Mount Sinai Roosevelt and St. Luke’s Hospital in New York City, and colleagues reviewed the electronic medical records for 4,278 HIV-infected patients aged ≥20 years in a racially and ethnically diverse urban HIV/AIDS clinic based in a large tertiary hospital. The National Cholesterol Education Program Adult Treatment Panel III goals were used to define low-density lipoprotein cholesterol (LDL-C) dyslipidemia, while hypertension was defined according to Joint National Committee VII criteria.

The researchers found that the prevalence of LDL-C dyslipidemia was 35%. Of the patients with LDL-C dyslipidemia, 90% were treated, and 75% of those treated were at goal. LDL-C goal was less likely to be met in patients in high-risk groups (56%), including known coronary heart disease (57%) or coronary heart disease equivalents (62%). Hypertension had a prevalence of 43%. While 75% of those with hypertension were treated, only 57% were at goal.

“As patients with HIV are at higher risk for CVD [cardiovascular disease] and living to an age where CVD is more common, it will be important to identify ways to better manage and control CVD risk factors in this patient population,” the authors write.

Full Text (subscription or payment may be required)